# OnCo record paradigm (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/paradigm/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "paradigm", "NCT02394795" ;
  schema:name "PARADIGM"@en ;
  schema:description "Proved that for RAS-normal tumours starting on the left side of the colon, an EGFR antibody beats the VEGF antibody as first partner for chemotherapy."@en ;
  schema:url <https://onco.cc/trials/paradigm/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02394795>, <https://ascopubs.org/doi/10.1200/JCO.2022.40.17_suppl.LBA1> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2015-05-29" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/folfox/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:terms <https://onco.cc/terms/sidedness/> ;
  onco:trials <https://onco.cc/trials/prime/>, <https://onco.cc/trials/calgb-80405/>, <https://onco.cc/trials/opus/>, <https://onco.cc/trials/cairo5/> ;
  onco:people <https://onco.cc/people/yoshino-takayuki/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/>, <https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/>, <https://onco.cc/key-papers/paper-paradigm-jama-2023/> .